Antiviral Pharmacology

Correct Answer

C — Peramivir

Rationale

Peramivir is classified as the intravenous neuraminidase inhibitor, administered as a single 600 mg intravenous infusion for uncomplicated influenza. Oseltamivir is an oral neuraminidase inhibitor administered as a prodrug. Zanamivir is a neuraminidase inhibitor administered by oral inhalation. Baloxavir is not a neuraminidase inhibitor — it is a cap-dependent endonuclease inhibitor administered orally as a single dose.

Correct Answer

D — Zanamivir

Rationale

Zanamivir is classified as a neuraminidase inhibitor administered by oral inhalation via a Diskhaler device. This route of administration delivers drug directly to the respiratory tract but is unsuitable for patients with underlying airways disease due to the risk of bronchospasm. Oseltamivir is an oral prodrug. Peramivir is the intravenous neuraminidase inhibitor. Baloxavir is a cap-dependent endonuclease inhibitor, not a neuraminidase inhibitor, and is administered orally.

Correct Answer

A — Baloxavir marboxil

Rationale

Baloxavir marboxil is classified as a cap-dependent endonuclease inhibitor. Its active form, baloxavir acid, targets the PA subunit of the influenza ribonucleic acid polymerase complex, blocking the cap-snatching step required for viral mRNA synthesis. This mechanism is distinct from all other licensed influenza antivirals. Oseltamivir and zanamivir are neuraminidase inhibitors. Amantadine is an M2 ion channel blocker. Baloxavir's single-dose oral administration regimen is another distinctive classification feature.

Correct Answer

C — Amantadine

Rationale

Amantadine is classified as an M2 ion channel blocker with antiviral activity restricted to influenza A viruses. Influenza B viruses possess a structurally distinct ion channel protein and are intrinsically resistant to adamantanes. Oseltamivir and zanamivir are neuraminidase inhibitors active against both influenza A and B. Baloxavir marboxil, a cap-dependent endonuclease inhibitor, is also active against both influenza A and B.

Correct Answer

B — Palivizumab

Rationale

Palivizumab is classified as a humanized monoclonal antibody targeting the respiratory syncytial virus F protein, administered as monthly intramuscular injections (15 mg per kilogram) during RSV season. Nirsevimab also targets the RSV F protein but is classified differently — it targets a prefusion-specific epitope and provides protection with a single dose covering the full RSV season rather than requiring monthly injections. Remdesivir is an intravenous nucleotide analogue prodrug. Ribavirin is a synthetic nucleoside analogue with broad-spectrum antiviral activity.

Correct Answer

D — Nirsevimab

Rationale

Nirsevimab is classified as a long-acting monoclonal antibody targeting a prefusion-specific epitope on the respiratory syncytial virus F protein, providing protection for an entire RSV season with a single intramuscular injection. This distinguishes it from palivizumab, which targets the RSV F protein but requires monthly injections and does not specifically target the prefusion conformation. The prefusion epitope targeting produces substantially more potent neutralizing activity. Ribavirin is a nucleoside analogue; remdesivir is a nucleotide analogue prodrug targeting ribonucleic acid polymerase.

Correct Answer

A — Neuraminidase cleaves sialic acid linkages to release newly assembled virions from infected cell surfaces; inhibiting neuraminidase causes virions to remain tethered to the cell surface and aggregate rather than dispersing through the respiratory tract

Rationale

Neuraminidase is required for the release step of the influenza replication cycle. After new virions assemble and bud from infected cells, neuraminidase cleaves sialic acid residues that tether the virions to the cell surface and to each other, allowing viral dispersal throughout the respiratory tract. Neuraminidase inhibitors competitively block the neuraminidase active site, preventing this cleavage and causing newly assembled virions to remain stuck to infected cell surfaces and aggregate rather than spreading to new target cells. Hemagglutinin — not neuraminidase — mediates viral attachment to sialic acid receptors; this step occurs before neuraminidase becomes relevant.

Correct Answer

C — Cross-resistance between oseltamivir and zanamivir is partial rather than complete for most clinically encountered neuraminidase mutations; H275Y preferentially reduces oseltamivir binding while largely preserving zanamivir binding at the neuraminidase active site

Rationale

Both oseltamivir and zanamivir inhibit neuraminidase by binding the conserved catalytic active site, but their binding contacts differ in detail. The H275Y mutation, which substitutes histidine for tyrosine at position 275, preferentially disrupts oseltamivir carboxylate binding affinity while largely preserving zanamivir's ability to bind the same active site. Cross-resistance between these two agents is therefore partial rather than complete for H275Y and most other clinically encountered neuraminidase mutations. This makes zanamivir or intravenous peramivir viable therapeutic alternatives when oseltamivir resistance is suspected or confirmed. Both oseltamivir and zanamivir are transition-state analogues that require no viral enzyme for activation; option D is pharmacologically inaccurate.

Correct Answer

D — Baloxavir acid inhibits the cap-dependent endonuclease activity of the influenza ribonucleic acid polymerase complex, blocking viral mRNA synthesis; substitutions in the endonuclease active site confer resistance during treatment

Rationale

Baloxavir acid binds to the PA subunit of the influenza ribonucleic acid polymerase complex and specifically inhibits its cap-dependent endonuclease activity. This enzyme cleaves capped host pre-messenger ribonucleic acid fragments — a process called cap-snatching — which are used to prime transcription of all influenza viral genes. Blocking this initiation step halts production of all influenza viral proteins simultaneously. Resistance emerges through substitutions at position 38 of the PA subunit (most commonly I38T), which reduce baloxavir acid binding affinity. These resistant strains retain full neuraminidase inhibitor susceptibility, providing an alternative therapeutic option. Options A, B, and C each misattribute baloxavir's mechanism to targets belonging to other drug classes.

Correct Answer

B — A single point mutation in the M2 transmembrane domain confers adamantane resistance while imposing minimal fitness cost on the virus, allowing resistant strains to spread efficiently in the community without drug selection pressure

Rationale

Adamantane resistance is conferred primarily by single amino acid substitutions within the M2 transmembrane domain, most commonly S31N. This mutation imposes minimal fitness cost on the virus — resistant strains replicate and transmit as efficiently as susceptible strains. In the 2005 to 2006 influenza season, adamantane resistance in circulating influenza A/H3N2 strains rose from approximately 2 percent to 96 percent within a single season, driven by the rapid spread of a single resistant clade rather than by drug-mediated selection within treated patients. The 2009 pandemic influenza A/H1N1 strain also carries S31N intrinsically. This pattern — high-level resistance, minimal fitness cost, community spread — explains why adamantanes are now clinically obsolete for influenza antiviral therapy.

Correct Answer

A — Influenza viral replication peaks within the first 24 to 48 hours of illness; neuraminidase inhibitors suppress active viral replication but cannot reverse the immune-mediated inflammation and cellular damage that has already occurred by the time symptoms are well established

Rationale

The clinical benefit of influenza antivirals is strongly time-dependent because peak viral replication occurs in the first 24 to 48 hours after symptom onset. Neuraminidase inhibitors work by suppressing active viral replication and limiting further viral spread. When initiated during peak replication, they reduce the viral burden before it peaks, shortening illness duration and reducing complication risk. After 48 hours, the peak of viral replication has passed and much of the symptomatic illness reflects immune-mediated inflammatory responses to viral damage already done — responses that antivirals cannot reverse. Influenza does not establish latency; resistance does not emerge within 48 hours through immune selection; and inflammatory cytokines do not meaningfully accelerate drug metabolism in this context.

Correct Answer

C — Ritonavir is a pharmacokinetic booster that inhibits CYP3A4 and P-glycoprotein, substantially increasing nirmatrelvir plasma concentrations and extending its half-life to enable twice-daily oral dosing

Rationale

Ritonavir in nirmatrelvir-ritonavir serves the same pharmacokinetic booster role as in HIV protease inhibitor regimens — it inhibits cytochrome P450 3A4 and P-glycoprotein, blocking nirmatrelvir metabolism and efflux, dramatically raising nirmatrelvir plasma concentrations. Without ritonavir boosting, nirmatrelvir would require much higher doses and more frequent administration to maintain therapeutic plasma levels. Ritonavir at the low dose used in Paxlovid (100 mg twice daily) provides no meaningful antiviral activity against SARS-CoV-2. This boosting mechanism also creates the drug interaction burden that makes nirmatrelvir-ritonavir complex to manage in patients on multiple medications, including many antiretroviral agents.

Correct Answer

D — Nirsevimab targets a prefusion-specific epitope on the RSV F protein that elicits more potent viral neutralization than the epitopes targeted by palivizumab, and its extended half-life allows a single dose to provide protection for an entire RSV season rather than requiring monthly injections

Rationale

Both nirsevimab and palivizumab are monoclonal antibodies that target the respiratory syncytial virus F fusion protein and prevent viral membrane fusion. The key distinction is the epitope targeted: nirsevimab specifically binds a prefusion-conformation epitope on the F protein. Antibodies targeting the prefusion conformation are substantially more potent neutralizers than those targeting postfusion or non-conformation-specific epitopes, because the prefusion state is what mediates membrane fusion. Nirsevimab also incorporates half-life extension modifications that allow a single intramuscular dose to maintain protective concentrations throughout an entire RSV season. Both are given by intramuscular injection; neither is oral or a small molecule.

Correct Answer

B — Remdesivir is a nucleotide analogue prodrug that inhibits ribonucleic acid-dependent ribonucleic acid polymerase after intracellular conversion to its active triphosphate form; intravenous administration is required because oral bioavailability of the prodrug is insufficient to achieve therapeutic plasma concentrations

Rationale

Remdesivir is a monophosphoramidate nucleotide analogue prodrug. After intravenous administration it is taken up by cells and converted intracellularly to remdesivir triphosphate, which inhibits ribonucleic acid-dependent ribonucleic acid polymerase by acting as a chain terminator after incorporation into nascent viral ribonucleic acid. This mechanism is active against a broad range of ribonucleic acid viruses including SARS-CoV-2. The intravenous route is required because oral bioavailability of the prodrug is insufficient for standard therapeutic use, limiting remdesivir to hospital settings. A three-day intravenous course is also approved for high-risk outpatients at facilities with infusion capacity. Remdesivir does not inhibit protease, spike protein, or neuraminidase.

Correct Answer

A — The 48-hour window applies to outpatient treatment for symptom reduction; in hospitalized patients with severe influenza, antiviral therapy is recommended regardless of time from symptom onset because ongoing viral replication continues to drive progression

Rationale

The 48-hour treatment window is derived from outpatient trials measuring median illness duration reduction in otherwise healthy adults. In patients with severe influenza requiring hospitalization — particularly those who are elderly, immunocompromised, or have underlying comorbidities — ongoing viral replication may continue well beyond 48 hours from symptom onset and continues to drive clinical deterioration. Current guidelines recommend oseltamivir for all hospitalized influenza patients regardless of time from symptom onset, because the potential benefit of viral load reduction in severe disease outweighs the diminished symptom duration benefit seen in outpatient populations. Neuraminidase inhibitors do not paradoxically worsen inflammation, and there is no pharmacological basis for a hard 48-hour concentration limit.

Correct Answer

C — Zanamivir or intravenous peramivir, because cross-resistance between oseltamivir and zanamivir is partial for H275Y, and these agents retain neuraminidase inhibitory activity against this strain

Rationale

The H275Y mutation preferentially disrupts oseltamivir carboxylate binding at the neuraminidase active site while largely preserving the binding contacts of zanamivir and peramivir. Because cross-resistance between neuraminidase inhibitors is partial rather than complete for H275Y, zanamivir by oral inhalation or intravenous peramivir are viable alternatives in oseltamivir-resistant influenza. Amantadine is not an appropriate choice because near-universal M2 resistance (S31N) in contemporary influenza A/H1N1 strains renders it inactive regardless of neuraminidase resistance status. Increasing the oseltamivir dose cannot overcome H275Y resistance because the mutation structurally alters the binding site rather than simply reducing drug affinity competitively. Ribavirin has no established role in influenza treatment outside of research settings.

Correct Answer

D — Amantadine provides no meaningful influenza protection because near-universal M2 resistance in contemporary influenza A strains renders it clinically inactive as an antiviral; his use is appropriate for Parkinson’s but should not be relied upon for influenza prevention

Rationale

The S31N mutation in the M2 transmembrane domain confers adamantane resistance and is present in virtually all currently circulating influenza A strains, including both H1N1 and H3N2 subtypes. Amantadine has no antiviral activity against influenza B because influenza B viruses possess a structurally distinct ion channel. This patient's amantadine therapy is entirely appropriate for his Parkinson's disease — amantadine functions as an N-methyl-D-aspartate receptor antagonist and dopamine agonist in the central nervous system, effects that are completely unrelated to M2 channel activity in influenza virus. However, it provides no influenza prophylaxis. Annual influenza vaccination and, if antiviral prophylaxis is indicated, a neuraminidase inhibitor or baloxavir should be considered.

Correct Answer

B — Adding a second ritonavir-containing regimen produces additive CYP3A4 inhibition, amplifying drug interactions with any CYP3A4-sensitive co-medications already affected by the existing ritonavir booster and requiring careful review of all concurrent medications

Rationale

Both the patient's existing antiretroviral regimen and nirmatrelvir-ritonavir contain ritonavir as a pharmacokinetic booster. Ritonavir's CYP3A4 and P-glycoprotein inhibitory effects are already present from the antiretroviral booster. Adding a second ritonavir source amplifies this inhibition and can raise plasma concentrations of any CYP3A4-sensitive co-medications substantially beyond what either ritonavir alone would produce. A comprehensive drug interaction review is required before initiating nirmatrelvir-ritonavir in any patient already on a ritonavir-boosted antiretroviral regimen. This does not mean nirmatrelvir-ritonavir is contraindicated — it often can be used with appropriate management — but the interaction profile is complex. Nirmatrelvir targets SARS-CoV-2 main protease and darunavir targets HIV protease; they do not compete for the same active site and do not cause mutual antiviral inhibition.